Grant of Options

RNS Number : 0483W

Synairgen plc

04 November 2014

 



PRESS RELEASE

4 November 2014

SYNAIRGEN PLC

("Synairgen" or "the Company")

Grant of options

Southampton, UK, 4 November 2014: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that on 3 November 2014 the Board of Synairgen granted options ("Options") over 1,086,997 ordinary shares of one pence each in the capital of the Company ("Ordinary Shares") at an exercise price of one pence per Ordinary Share. The Options represent in aggregate 1.19 per cent of the existing issued share capital.

The Options are issued under the Company's existing Long Term Incentive Plan and are exercisable between 3 November 2017 and 2 November 2024, subject to achievement of performance criteria related to the increase in the total shareholder return of the Company.

The following Options were issued to directors of the Company on 3 November 2014:

Director	Options Issued
Richard Marsden	313,827
Dr. Phillip Monk	233,425
John Ward	285,297

Following the issue of the Options, the interests of the directors of the Company at 3 November 2014 are as follows:

Director	Total options issued	Ordinary shares	Total interest	Percentage holding of fully diluted share capital
Richard Marsden	1,949,511	110,972	2,060,483	2.13%
Dr. Phillip Monk	866,413	161,710	1,028,123	1.06%
John Ward	1,322,283	243,912	1,566,195	1.62%
Simon Shaw (Note 1)	-	1,408,879	1,408,879	1.46%
Iain Buchanan	212,765	112,741	325,506	0.34%
Dr. David Campbell	-	294,259	294,259	0.30%
Paul Clegg (Note 2)	250,000	204,244	454,244	0.47%
Prof. Stephen Holgate (Note 3)	-	858,360	858,360	0.89%

Note 1. Simon Shaw's shareholding includes 40,299 shares held in his pension plan.

Note 2. Paul Clegg's shareholding includes 180,149 shares held in his pension plan.

Note 3. The holding of Professor Stephen Holgate includes 1,923 shares owned by his wife, Elizabeth Holgate.

ENDS

For further information, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

finnCap

Geoff Nash, Christopher Raggett (Corporate Finance)

Stephen Norcross, Simon Johnson (Corporate Broking)

Tel: + 44 (0) 20 7220 0500

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Jessica Hodgson / Laura Thornton

[e-mail]

Tel: [phone]

Notes for Editors

About Synairgen 

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma and COPD, uses its differentiating human biology Biobank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging its scientific and clinical facilities at Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The Biobank of human samples is used in these models to increase confidence in the likelihood of successful drug development. Core to Synairgen's business strategy is the realisation of value via licensing transactions - validated in June 2014 by the SNG001 agreement formed with AstraZeneca. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com 

 

END

 

 

RDSEANFDEDPLFFF